BCN Peptides is working in a research program having as therapeutic target Lysosomal Storage diseases, a group or rare inherited metabolic disorders that result from defects in lysosomal function.

The project, enclosed in “Nuclis d’Innovació Tecnològica” program from ACCIÓ, is cofinanced with the European Union FEDER funds.

BCN Peptides supports IDP-Pharma in the development of a new chemical entity aimed to treat Multiple Myeloma.

The collaboraive project has been granted with funds from the European Union FEDER via ACCIO and its programme “Nuclis d’Innovació Tecnològica”.